Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to ...

Alector (NASDAQ:ALEC) is scheduled to announce Q4 earnings results on Wednesday, February 26th, after market close.The ...

AbbVie is pulling out of its collaboration with Alector on the development of Alzheimer's disease candidate AL003, which aims to tackle the neurodegenerative disease by restoring reduced immune ...

Alector has launched an $208 million stock market offering as it ramps up clinical trials with AbbVie into a drug that aims to tackle Alzheimer’s by modifying the brain’s immune system.

Alector (ALEC) announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of ...

Alector said Gary Romano is stepping down as medical chief after about three years in the role, and will be replaced by Giacomo Salvadore. The late-stage clinical biotechnology company with a ...

Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- "It has been a privilege to work alongside the talented team at Alector to advance a pipeline of therapies designed to ...

SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating ...

April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...